| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $206,101 | 1 | 33 |
Sells | $113,181 | 2 | 67 |
| Lynx1 Capital Management LP | 10 percent owner | 1 | $206,101 | 0 | $0 | $206,101 |
| Borthwick Kathleen | CFO | 0 | $0 | 1 | $38,022 | $-38,022 |
| Chou William | PRESIDENT AND CEO | 0 | $0 | 1 | $75,159 | $-75,159 |
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the …
Over the last 12 months, insiders at Passage Bio, Inc. have bought $206,101 and sold $113,181 worth of Passage Bio, Inc. stock.
On average, over the past 5 years, insiders at Passage Bio, Inc. have bought $1.29M and sold $239,838 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lynx1 Capital Management LP (10 percent owner) — $206,101.
The last purchase of 50,055 shares for transaction amount of $206,101 was made by Lynx1 Capital Management LP (10 percent owner) on 2026‑06‑25.
| 2026-06-25 | Lynx1 Capital Management LP | 10 percent owner | 50,055 1.4838% | $4.12 | $206,101 | +5.08% | ||
| 2026-01-08 | Sale | Chou William | PRESIDENT AND CEO | 4,076 0.129% | $18.44 | $75,159 | -72.04% | |
| 2026-01-08 | Sale | Borthwick Kathleen | CFO | 2,062 0.0653% | $18.44 | $38,022 | -72.04% | |
| 2025-09-15 | Lynx1 Capital Management LP | 10 percent owner | 11,900 0.3765% | $6.99 | $83,175 | +6.91% | ||
| 2025-09-12 | Lynx1 Capital Management LP | 10 percent owner | 19,783 0.6215% | $6.99 | $138,299 | +6.14% | ||
| 2025-09-11 | Lynx1 Capital Management LP | 10 percent owner | 325 0.01% | $6.96 | $2,261 | +6.60% | ||
| 2025-07-24 | Lynx1 Capital Management LP | 10 percent owner | 66,423 2.1223% | $5.71 | $379,455 | +30.54% | ||
| 2025-07-23 | Lynx1 Capital Management LP | 10 percent owner | 49,302 1.5693% | $5.74 | $283,033 | +29.41% | ||
| 2025-07-22 | Lynx1 Capital Management LP | 10 percent owner | 13,123 0.4032% | $5.44 | $71,338 | +31.92% | ||
| 2025-06-26 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 213,257 0.3431% | $0.33 | $70,375 | +16.36% | |
| 2025-06-25 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 138,800 0.2261% | $0.33 | $45,804 | +17.79% | |
| 2025-06-24 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 231,600 0.371% | $0.35 | $81,060 | +9.25% | |
| 2025-04-24 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 68,195 0.1045% | $0.32 | $21,822 | +22.31% | |
| 2025-04-23 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 89,328 0.1454% | $0.34 | $30,372 | +18.30% | |
| 2025-04-22 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 78,049 0.122% | $0.34 | $26,537 | +13.57% | |
| 2025-04-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 77,090 0.1169% | $0.33 | $25,440 | +20.83% | |
| 2025-04-16 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 61,638 0.0935% | $0.33 | $20,341 | +20.82% | |
| 2025-04-15 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 10,326 0.018% | $0.38 | $3,924 | +7.72% | |
| 2025-02-11 | Sale | Borthwick Kathleen | CFO | 3,183 0.0048% | $0.53 | $1,686 | -24.79% | |
| 2025-01-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 79,024 0.1279% | $0.60 | $47,414 | -33.42% |
| Lynx1 Capital Management LP | 10 percent owner | 673759 20.9384% | $2.29M | 11 | 0 | <0.0001% |
| OrbiMed Capital GP VII LLC | 6537923 203.1793% | $22.23M | 1 | 0 | <0.0001% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 6066343 188.524% | $20.63M | 10 | 25 | <0.0001% |
| Heron Patrick J | 5009219 155.6717% | $17.03M | 1 | 0 | <0.0001% | |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 5009219 155.6717% | $17.03M | 1 | 0 | <0.0001% |
| Ratcliffe Liam | director | 2616630 81.3171% | $8.9M | 1 | 0 | <0.0001% |
| Woiwode Thomas | 933352 29.0058% | $3.17M | 1 | 0 | <0.0001% | |
| Versant Venture Capital VI, L.P. | 10 percent owner | 933352 29.0058% | $3.17M | 1 | 0 | <0.0001% |
| Yamada Tadataka | director | 656149 20.3912% | $2.23M | 1 | 0 | <0.0001% |
| Quigley Jill M. | Chief Operating Officer | 295284 9.1766% | $1M | 1 | 2 | <0.0001% |
| Cale Edgar B. | GC & Corporate Secretary | 45995 1.4294% | $156,383.00 | 1 | 1 | <0.0001% |
| Fotopoulos Alexandros | Chief Technical Officer | 28693 0.8917% | $97,556.20 | 1 | 2 | <0.0001% |
| Countouriotis Athena | director | 18900 0.5874% | $64,260.00 | 2 | 0 | +16.32% |
| Goldsmith Bruce A | CEO and President | 15983 0.4967% | $54,342.20 | 3 | 0 | <0.0001% |
| Morris Richard Steven | Chief Financial Officer | 5454 0.1695% | $18,543.60 | 2 | 0 | <0.0001% |
| Islam Saqib | director | 5000 0.1554% | $17,000.00 | 1 | 0 | <0.0001% |
| Kapadia Sandip | director | 0 0% | $0 | 1 | 1 | <0.0001% |
$18,815,063 | 62 | -6.45% | $13.7M | |
$1,993,425 | 46 | -21.91% | $13.95M | |
Passage Bio, Inc. (PASG) | $95,567,744 | 39 | -17.01% | $10.94M |
$30,257,839 | 29 | -15.72% | $12M | |
$76,600 | 22 | -38.58% | $10.49M |
| Increased Positions | 11 | +26.83% | 225,217 | +5.55% |
| Decreased Positions | 14 | -34.15% | 3M | -64.54% |
| New Positions | 6 | New | 197,826 | New |
| Sold Out Positions | 7 | Sold Out | 155,417 | Sold Out |
| Total Postitions | 38 | -7.32% | 2M | -58.99% |
| Lynx1 Capital Management Lp | $7,291.00 | 20.79% | 623,704 | +160,856 | +34.75% | 2025-09-30 |
| Vestal Point Capital, Lp | $3,565.00 | 10.17% | 305,000 | 0 | 0% | 2025-09-30 |
| Erste Asset Management Gmbh | $1,435.00 | 4.09% | 122,790 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $1,368.00 | 3.9% | 117,030 | +15,002 | +14.7% | 2025-09-30 |
| Renaissance Technologies Llc | $1,178.00 | 3.36% | 100,789 | +29,969 | +42.32% | 2025-09-30 |
| New Leaf Venture Partners, L.L.C. | $1,022.00 | 2.91% | 87,426 | -2M | -96.5% | 2025-09-30 |
| Tang Capital Management Llc | $877.00 | 2.5% | 75,000 | 0 | 0% | 2025-09-30 |
| Orbimed Advisors Llc | $690.00 | 1.97% | 59,046 | -243,719 | -80.5% | 2025-09-30 |
| Blackrock, Inc. | $348.00 | 0.99% | 29,749 | +6 | +0.02% | 2025-09-30 |
| Geode Capital Management, Llc | $319.00 | 0.91% | 27,283 | +354 | +1.31% | 2025-09-30 |